Please login to the form below
drug launch
This page shows the latest drug launch news and features for those working in and with pharma, biotech and healthcare.
Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19
Encouraged and spurred on by the initial efficacy of Actemra, Kevzara’s owners are carrying out their own trials of the drug as a treatment for the novel coronavirus, with Regeneron ... 16 sites and evaluating the drug’s effect on fever and
Latest news
-
Shionogi launches thrombocytopenia treatment Mulpleo in the UK
New treatment option for patients with severe liver disease. The European subsidiary of Japanese pharma company Shionogi has announced the launch of its thrombocytopenia drug Mulpleo in the UK, offering a ... The positive recommendations of the drug were
-
Moderna and GSK advance coronavirus vaccine candidates
The drug was originally being developed as a treatment for the infectious diseases Ebola and Marbug virus. ... However, despite successfully copying and manufacturing the drug, BrightGene has said it will not launch the drug until it has received
-
Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD
New drug due for launch in Europe in the second quarter. ... duration. The new drug made $35m in the fourth quarter following its launch in the US in October, which Tschudin said was “a great start” with 84% of retina specialists having
-
China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir
However, Gilead which holds all patents around the development and production of the drug – including for its development as a treatment for coronavirus. ... Although BrightGene has said it has successfully developed and manufactured copies of the drug,
-
New drugs drive Novo Nordisk despite insulin price pressures
This included a boost from GLP-1 agonist Ozempic (semaglutide) which has been climbing solidly since its launch, as demand increases for the drug. ... Sales of the drug reached DKK11.2bn ($1.6bn), up from DKK1.8bn last year.
More from news
Approximately 1 fully matching, plus 201 partially matching documents found.
Latest Intelligence
-
Alzheimer’s: the search for a cure
However, the situation has changed dramatically since then, with Biogen preparing for a drug launch that could make aducanumab a blockbuster and reinvigorate interest in amyloid beta. ... A lot is resting on the US Food and Drug Administration’s (FDA)
-
Cooking up a co-creation feast – beyond vanilla
Another challenge for us as agencies is to nudge our clients to involve the end user earlier and earlier in the drug development process. ... Often, we co-design material to support the use of a drug during its clinical development.
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
This year’s report additionally features insight from the new Cortellis Analytics – Drug Timeline &Success Rates module, an analytic that predicts the probability of launch and timeline to market for ongoing ... The company expects to launch the drug
-
Launch trends 2019
What are the big trends in pharma and biotech drug launches for 2019? ... Large companies entering competitive spaces are planning for increased launch budgets to compete and win.
-
Drug launches to watch in 2019
Camurus is currently preparing to launch the drug in the first European markets as early as January, and expects ‘substantial’ sales of the treatment during 2019, although it will take three ... Compared with a similar treatment marketed by Indivior,
More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.
Latest appointments
-
NDA Group appoints Alison McGregor as its principal consultant
She joins the group following a new US office launch. Drug development consultancy, NDA Group, has appointed Alison McGregor as its principal consultant following the opening of its new US office
-
Medicines Discovery Catapult appoints CEO
Chris' experience of leading companies operating in life sciences combined with his in-depth knowledge of drug discovery will be of tremendous value to the company.”. ... The Catapult will engage the UK's experienced drug discovery talent and help
-
Astellas promotes John Demaree
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
-
Paolo Paoletti named as executive chairman of Kesios
Paoletti was formerly the first appointed president of GSK Oncology, where he was responsible for the overall oncology business within the firm and oversaw activities from early drug discovery through to ... clinical development, launch and life cycle
-
Purdue looks to Merck for new CEO
His previous roles include president of Merck US, during which time he helped to launch the hepatitis C drug Victrelis (boceprevir) and led the acquisition of ophthalmology company Inspire Pharmaceuticals.
More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest from PMHub
-
Top 5 tips for a multi-indication product launch
The term ‘launch excellence’ conjures up images of a traditional brand launch in which a new drug is introduced to the market. ... The rationale here makes sense – maximising your resources on a new launch will create.
-
Lighthouse Medical Communications US continues its expansion with two new hires to its client services team
After graduation, Danni interned at Novartis Pharmaceuticals on the marketing and commercial team, working on the launch of their metastatic breast cancer drug.
-
It's time to change the conversation
of drug being promoted and how this is clinically differentiated in its competitive environment. ... connections. While promotional spend on their drug Tysabri at launch was focused on specialist detailing and medical events, the promotional mix has
-
Excellence in oncology: Developing an effective biomarker strategy
Physicians feel confident that they are offering an effective drug, which is at the cutting-edge of medicine. ... Manufacturers with an innovator drug now in development will usually search for a suitable biomarker to launch alongside the drug.
-
Brand leaders in RA will lose market share, predict rheumatologists
The growing use of non TNF-inhibitor biologics, along with the gradual launch of biosimilars and new small molecules, has the potential to dramatically change the market landscape in the medium ... Moreover, while Pfizer expects the launch of the drug in
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- FDA approves Roche’s Actemra COVID-19 trial
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
